question_id,date,category,question_text,baseline_success,baseline_actually_answered,baseline_has_expected,baseline_confidence,baseline_text,baseline_error,baseline_time,baseline_input_tokens,baseline_output_tokens,togomcp_success,togomcp_has_expected,togomcp_confidence,togomcp_text,togomcp_error,togomcp_time,togomcp_input_tokens,togomcp_output_tokens,togomcp_cache_creation_input_tokens,togomcp_cache_read_input_tokens,tools_used,tool_details,value_add,expected_answer,notes
61,2026-02-01,Structured Query,What high-quality kinase structures have been published with good R-factors and resolution below 2 Angstroms?,True,False,True,0.6,"I can provide some examples of high-quality kinase structures that have been published with excellent statistics, though I should note that without access to current databases, I'm working from my training knowledge:

## Notable High-Resolution Kinase Structures:

**Classic Examples:**

1. **CDK2 (Cyclin-Dependent Kinase 2)** - Multiple structures at ~1.5-1.9 Å resolution with R-factors around 0.18-0.20. CDK2 has been extensively studied with various inhibitors.

2. **PKA (Protein Kinase A/cAMP-dependent protein kinase)** - Several structures below 2.0 Å, including some at ~1.2-1.6 Å with excellent R-factors (~0.16-0.19).

3. **Aurora Kinase A** - Multiple structures at 1.5-1.9 Å resolution with good R-factors.

4. **ABL (Abelson tyrosine kinase)** - Several high-quality structures around 1.5-2.0 Å, particularly important for cancer research.

5. **p38 MAP Kinase** - Numerous structures with resolution better than 2.0 Å and R-factors typically below 0.20.

**Quality Metrics:**
- Resolutions: typically 1.2-1.95 Å
- R-factors: generally 0.15-0.20
- R-free: usually 0.18-0.25

These structures have been valuable for structure-based drug design and understanding kinase catalytic mechanisms. Many were co-crystallized with ATP analogs, inhibitors, or substrate peptides.

For current, specific PDB codes and the latest high-quality structures, you would need to search the Protein Data Bank directly.",,11.341438055038452,63,422,True,True,0.7,"Based on my search of the PDB database, here are some **high-quality kinase structures** with excellent resolution (below 2.0 Å) and good R-factors:

## Ultra-High Resolution Kinase Structures:

### **1. PDB 4WIH - 1.14 Å resolution** ⭐ Outstanding
- **cAMP-dependent Protein Kinase A** from *Cricetulus griseus* (Chinese hamster)
- R-free: 0.191, R-work: 0.177
- Exceptional quality - among the highest resolution kinase structures

### **2. PDB 1H10 - 1.40 Å resolution**
- **Pleckstrin Homology Domain of Protein Kinase B/Akt** bound to Ins(1,3,4,5)-tetrakisphosphate
- High-resolution structure important for understanding Akt regulation

### **3. PDB 2A2A - 1.47 Å resolution**
- **Death-Associated Protein Kinase (DAPK)** in autoinhibited conformation
- R-free: 0.207, R-work: 0.150
- Excellent quality metrics

### **4. PDB 1MP8 - 1.60 Å resolution**
- **Focal Adhesion Kinase (FAK)**
- R-free: 0.230, R-work: 0.179
- Important for cell adhesion and migration studies

### **5. PDB 1MQ4 - 1.60 Å resolution**
- **Aurora-A Protein Kinase**
- R-free: 0.273, R-work: 0.225
- Key mitotic kinase structure

### **6. PDB 3X2W - 1.70 Å resolution**
- **Michaelis Complex of cAMP-dependent Protein Kinase Catalytic Subunit**
- R-free: 0.198, R-work: 0.163
- Captures catalytic mechanism

### **7. PDB 4W9W - 1.72 Å resolution**
- **BMP-2-Inducible Kinase (BIKe)** with small molecule AZD-7762
- R-free: 0.195, R-work: 0.166
- High-quality drug-bound structure

### **8. PDB 3X2V - 1.77 Å resolution**
- **Michaelis-like Complex of PKA Catalytic Subunit**
- R-free: 0.230, R-work: 0.183
- Important for understanding substrate recognition

### **9. PDB 3FHR - 1.90 Å resolution**
- **MAPK-Activated Protein Kinase 3 (MK3)** with inhibitor
- R-free: 0.267, R-work: 0.226
- High-resolution complex with inhibitor

### **10. PDB 4WSQ - 1.95 Å resolution**
- **Adaptor Protein 2 Associated Kinase (AAK1)** with inhibitor
- R-free: 0.208, R-work: 0.181
- Excellent quality for drug discovery

## Key Points:
- **Best overall**: 4WIH at 1.14 Å is exceptionally high resolution for a kinase
- **Best R-factors**: 2A2A with R-work of 0.150 is outstanding
- **Diverse kinases**: PKA, FAK, Aurora, DAPK, MAPKs, and receptor tyrosine kinases
- Most structures have R-free < 0.25 and R-work < 0.22, indicating excellent model quality

These structures are ideal for detailed mechanistic studies, structure-based drug design, and understanding catalytic mechanisms at atomic resolution.",,101.03162002563477,49,5026,7797,355829,"mcp__togomcp__search_pdb_entity, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__search_pdb_entity, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__search_pdb_entity, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""kinase resolution below 2.0 angstrom"", ""limit"": 50}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX PDBo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX dcterms: <http://purl.org/dc/terms/>\n\nSELECT DISTINCT ?pdb_id ?title ?resolution ?r_free ?r_work\nWHERE {\n  ?entry rdf:type PDBo:datablock ;\n         dcterms:title ?title ;\n         PDBo:has_pdbx_database_statusCategory ?status ;\n         PDBo:has_reflnsCategory ?reflns ;\n         PDBo:has_refineCategory ?refine .\n  \n  ?status PDBo:has_pdbx_database_status ?status_details .\n  ?status_details PDBo:pdbx_database_status.entry_id ?pdb_id .\n  \n  ?reflns PDBo:has_reflns ?reflns_details .\n  ?reflns_details PDBo:reflns.d_resolution_high ?resolution .\n  \n  ?refine PDBo:has_refine ?refine_details .\n  ?refine_details PDBo:refine.ls_R_factor_R_free ?r_free ;\n                  PDBo:refine.ls_R_factor_R_work ?r_work .\n  \n  FILTER(CONTAINS(LCASE(?title), \""kinase\""))\n  FILTER(?resolution < 2.0)\n  FILTER(?r_free < 0.25)\n  FILTER(?r_work < 0.22)\n}\nORDER BY ?resolution\nLIMIT 20""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX PDBo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX dcterms: <http://purl.org/dc/terms/>\n\nSELECT DISTINCT ?pdb_id ?title ?resolution\nWHERE {\n  ?entry rdf:type PDBo:datablock ;\n         dcterms:title ?title .\n  \n  ?entry PDBo:has_pdbx_database_statusCategory/PDBo:has_pdbx_database_status ?status .\n  ?status PDBo:pdbx_database_status.entry_id ?pdb_id .\n  \n  ?entry PDBo:has_reflnsCategory/PDBo:has_reflns ?reflns .\n  ?reflns PDBo:reflns.d_resolution_high ?resolution .\n  \n  FILTER(CONTAINS(LCASE(?title), \""kinase\""))\n  FILTER(?resolution < 2.0)\n}\nORDER BY ?resolution\nLIMIT 30""}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""protein kinase high resolution structure"", ""limit"": 30}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX PDBo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX dcterms: <http://purl.org/dc/terms/>\n\nSELECT ?pdb_id ?resolution ?r_free ?r_work\nWHERE {\n  VALUES ?pdb_id { \""1AKY\"" \""2AKY\"" \""3FHR\"" \""1H10\"" \""2A2A\"" \""1MQ4\"" \""4W9W\"" \""4WSQ\"" \""1SYK\"" \""1JLU\"" \""1JBP\"" \""1MP8\"" \""1MQB\"" }\n  \n  ?entry a PDBo:datablock .\n  ?entry PDBo:has_pdbx_database_statusCategory ?status_cat .\n  ?status_cat PDBo:has_pdbx_database_status ?status .\n  ?status PDBo:pdbx_database_status.entry_id ?pdb_id .\n  \n  OPTIONAL {\n    ?entry PDBo:has_reflnsCategory ?reflns_cat .\n    ?reflns_cat PDBo:has_reflns ?reflns .\n    ?reflns PDBo:reflns.d_resolution_high ?resolution .\n  }\n  \n  OPTIONAL {\n    ?entry PDBo:has_refineCategory ?refine_cat .\n    ?refine_cat PDBo:has_refine ?refine .\n    ?refine PDBo:refine.ls_R_factor_R_free ?r_free .\n    ?refine PDBo:refine.ls_R_factor_R_work ?r_work .\n  }\n}\nORDER BY ?resolution""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX PDBo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX dcterms: <http://purl.org/dc/terms/>\n\nSELECT ?pdb_id ?title ?resolution ?r_free ?r_work\nWHERE {\n  ?entry a PDBo:datablock ;\n         dcterms:title ?title .\n  \n  ?entry PDBo:has_pdbx_database_statusCategory/PDBo:has_pdbx_database_status ?status .\n  ?status PDBo:pdbx_database_status.entry_id ?pdb_id .\n  \n  ?entry PDBo:has_reflnsCategory/PDBo:has_reflns ?reflns .\n  ?reflns PDBo:reflns.d_resolution_high ?resolution .\n  \n  OPTIONAL {\n    ?entry PDBo:has_refineCategory/PDBo:has_refine ?refine .\n    ?refine PDBo:refine.ls_R_factor_R_free ?r_free ;\n            PDBo:refine.ls_R_factor_R_work ?r_work .\n  }\n  \n  FILTER(CONTAINS(LCASE(?title), \""kinase\""))\n  FILTER(?resolution < 2.0)\n  FILTER(?r_free < 0.25 || !BOUND(?r_free))\n}\nORDER BY ?resolution\nLIMIT 25""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX PDBo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX dcterms: <http://purl.org/dc/terms/>\n\nSELECT DISTINCT ?pdb_id ?resolution ?r_free ?r_work\nWHERE {\n  ?entry a PDBo:datablock .\n  \n  ?entry PDBo:has_pdbx_database_statusCategory/PDBo:has_pdbx_database_status ?status .\n  ?status PDBo:pdbx_database_status.entry_id ?pdb_id .\n  \n  ?entry PDBo:has_reflnsCategory/PDBo:has_reflns ?reflns .\n  ?reflns PDBo:reflns.d_resolution_high ?resolution .\n  \n  ?entry PDBo:has_refineCategory/PDBo:has_refine ?refine .\n  ?refine PDBo:refine.ls_R_factor_R_free ?r_free ;\n          PDBo:refine.ls_R_factor_R_work ?r_work .\n  \n  ?entry PDBo:has_struct_keywordsCategory/PDBo:has_struct_keywords ?keywords .\n  ?keywords PDBo:struct_keywords.pdbx_keywords ?keyword_text .\n  \n  FILTER(CONTAINS(LCASE(?keyword_text), \""kinase\""))\n  FILTER(?resolution < 2.0)\n  FILTER(?r_free < 0.25)\n  FILTER(?r_work < 0.22)\n}\nORDER BY ?resolution\nLIMIT 30""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX PDBo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\n\nSELECT ?pdb_id ?resolution ?r_free ?r_work\nWHERE {\n  VALUES ?pdb_id { \""1CDK\"" \""1ATP\"" \""3FHR\"" \""4MNE\"" \""4WSQ\"" \""4W9W\"" \""1H10\"" \""2A2A\"" \""1MP8\"" \""3X2U\"" \""3X2V\"" \""3X2W\"" \""4WIH\"" }\n  \n  ?entry a PDBo:datablock ;\n         PDBo:has_pdbx_database_statusCategory/PDBo:has_pdbx_database_status/PDBo:pdbx_database_status.entry_id ?pdb_id .\n  \n  OPTIONAL {\n    ?entry PDBo:has_reflnsCategory/PDBo:has_reflns ?reflns .\n    ?reflns PDBo:reflns.d_resolution_high ?resolution .\n  }\n  \n  OPTIONAL {\n    ?entry PDBo:has_refineCategory/PDBo:has_refine ?refine .\n    ?refine PDBo:refine.ls_R_factor_R_free ?r_free ;\n            PDBo:refine.ls_R_factor_R_work ?r_work .\n  }\n}\nORDER BY ?resolution""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX PDBo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX dcterms: <http://purl.org/dc/terms/>\n\nSELECT ?pdb_id ?title\nWHERE {\n  VALUES ?pdb_id { \""4WIH\"" \""1H10\"" \""2A2A\"" \""1MP8\"" \""3X2W\"" \""4W9W\"" \""3X2V\"" \""3FHR\"" \""4WSQ\"" }\n  \n  ?entry a PDBo:datablock ;\n         dcterms:title ?title ;\n         PDBo:has_pdbx_database_statusCategory/PDBo:has_pdbx_database_status/PDBo:pdbx_database_status.entry_id ?pdb_id .\n}""}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""CDK kinase PKA Aurora tyrosine kinase"", ""limit"": 40}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX PDBo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\n\nSELECT ?pdb_id ?resolution ?r_free ?r_work\nWHERE {\n  ?entry a PDBo:datablock ;\n         PDBo:has_pdbx_database_statusCategory/PDBo:has_pdbx_database_status/PDBo:pdbx_database_status.entry_id ?pdb_id .\n  \n  ?entry PDBo:has_reflnsCategory/PDBo:has_reflns ?reflns .\n  ?reflns PDBo:reflns.d_resolution_high ?resolution .\n  \n  OPTIONAL {\n    ?entry PDBo:has_refineCategory/PDBo:has_refine ?refine .\n    ?refine PDBo:refine.ls_R_factor_R_free ?r_free ;\n            PDBo:refine.ls_R_factor_R_work ?r_work .\n  }\n  \n  FILTER(?resolution < 1.5)\n  FILTER(BOUND(?r_free))\n  FILTER(?r_free < 0.25)\n}\nORDER BY ?resolution\nLIMIT 50""}}]",CRITICAL,High-quality kinase structures such as phosphoglycerate kinase (16PK) at 1.6 Å with R-work < 0.20,"COMPLEX QUERY requiring multi-criteria filtering with numeric conversion.

Databases/Resources: PDB

Knowledge Required:
- xsd:decimal() conversion for BOTH resolution AND R-factor (both stored as strings)
- struct_keywords for classification filtering
- citation category for publication
- X-ray diffraction method filter
- Multiple FILTER conditions

Without proper knowledge: Numeric filters return incorrect results without type conversion.

Verified in pdb_exploration.md Pattern 3 (Multi-Criteria Structure Quality Filtering)."
62,2026-02-01,Structured Query,Which GO biological processes relate to mitochondria and transport?,True,True,True,0.8181818181818182,"Based on my training knowledge, here are some key GO (Gene Ontology) biological processes that relate to both mitochondria and transport:

## Major Mitochondrial Transport Processes:

1. **Mitochondrial protein import** (GO:0030150)
   - Protein transport into mitochondria
   - Protein import into mitochondrial matrix
   - Protein import into mitochondrial inner membrane
   - Protein import into mitochondrial outer membrane

2. **Mitochondrial transport** (GO:0006839)
   - General term for transport processes in/out of mitochondria

3. **Ion transport processes:**
   - Mitochondrial calcium ion transport
   - Mitochondrial iron ion transport
   - Mitochondrial potassium ion transport
   - Mitochondrial proton transport

4. **Metabolite transport:**
   - Mitochondrial ATP transport
   - Mitochondrial ADP transport
   - Fatty acid transport into mitochondria
   - Pyruvate transport into mitochondria

5. **Mitochondrial DNA/RNA transport:**
   - RNA import into mitochondria
   - tRNA import into mitochondria

6. **Mitochondrial fusion and fission** (related to organelle transport):
   - Mitochondrial fusion
   - Mitochondrial fission
   - Mitochondrial transport along microtubule

These processes are critical for mitochondrial function, energy metabolism, and cellular homeostasis. The specific GO term identifiers would provide more precise definitions and hierarchical relationships within the Gene Ontology structure.",,7.8073649406433105,49,364,True,True,0.6363636363636364,"Here are the key GO biological processes related to mitochondria and transport:

## General Mitochondrial Transport
- **GO:0006839 - mitochondrial transport**: Transport of substances into, out of, or within a mitochondrion (the main parent term)

## Specific Import/Export Processes
- **GO:0170036 - import into the mitochondrion**: Includes protein import and various metabolite import processes
- **GO:0170037 - export from the mitochondrion**: Transport from mitochondrial matrix to cytosol
- **GO:1990542 - mitochondrial transmembrane transport**: Transport across mitochondrial membranes

## Metabolite Transport
- **GO:0006850 - pyruvate import into mitochondria**: Pyruvate transport from cytosol into mitochondrial matrix
- **GO:0048250 - iron import into the mitochondrion**: Iron transport from cytosol into mitochondrial matrix
- **GO:1990575 - mitochondrial L-ornithine transmembrane transport**: L-ornithine transport across mitochondrial membranes

## RNA/Ribosomal Component Transport
- **GO:0019090 - mitochondrial rRNA export from mitochondrion**: Ribosomal RNA transport from mitochondrial matrix to cytosol
- **GO:0019091 - mitochondrial lrRNA export from mitochondrion**: Large ribosomal subunit RNA export
- **GO:0019092 - mitochondrial srRNA export from mitochondrion**: Small ribosomal subunit RNA export

## Protein Transport
- **GO:0045041 - protein import into mitochondrial intermembrane space**: Protein import between inner and outer mitochondrial membranes

## Membrane Permeability & Regulation
- **GO:0046902 - regulation of mitochondrial membrane permeability**: Regulates permeability for transport across mitochondrial membranes
- **GO:1902686 - mitochondrial outer membrane permeabilization involved in programmed cell death**: Membrane permeabilization during apoptosis

These processes are essential for mitochondrial function, including energy metabolism, protein import, metabolite exchange, and cellular signaling.",,19.112274169921875,8,634,20975,52260,mcp__ols__searchClasses,"[{""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""mitochondria transport"", ""ontologyId"": ""go"", ""pageSize"": 20}}]",VALUABLE,"GO terms with both mitochondria and transport in their definitions, related to mitochondrial transport processes","COMPLEX QUERY requiring boolean search knowledge.

Databases/Resources: GO

Knowledge Required:
- bif:contains with boolean syntax: ""('mitochondria' AND 'transport')""
- Proper quoting for keywords
- STR() for namespace filtering
- FROM clause for consistent results

Without proper knowledge: Cannot construct boolean text search correctly.

Verified in go_exploration.md Pattern 3."
63,2026-02-01,Integration,Find pathogenic variants in BRCA1 and their associated disease conditions.,True,True,True,0.7692307692307693,"I can provide information about pathogenic variants in BRCA1 and their associated disease conditions based on established medical knowledge.

## BRCA1 Pathogenic Variants and Associated Diseases

### Primary Associated Conditions:

1. **Hereditary Breast and Ovarian Cancer Syndrome (HBOC)**
   - Breast cancer (lifetime risk: 55-72%)
   - Ovarian cancer (lifetime risk: 39-44%)
   - Earlier age of onset compared to sporadic cases

2. **Other Cancers with Increased Risk:**
   - Pancreatic cancer
   - Prostate cancer (in males)
   - Melanoma (modest increased risk)

### Common Pathogenic Variant Types:

**Frameshift Mutations:**
- c.68_69delAG (185delAG) - common in Ashkenazi Jewish population
- c.5266dupC (5382insC) - common in Ashkenazi Jewish and Eastern European populations
- Various other small insertions/deletions causing frameshifts

**Nonsense Mutations:**
- c.4327C>T (p.Arg1443Ter)
- c.5503C>T (p.Arg1835Ter)
- Multiple others creating premature stop codons

**Splice Site Mutations:**
- c.81-2A>G
- Various mutations affecting RNA splicing

**Large Deletions/Duplications:**
- Whole exon or multi-exon deletions
- Detected by methods like MLPA

### Clinical Significance:

Pathogenic BRCA1 variants result in loss of function of the BRCA1 protein, which is critical for DNA repair through homologous recombination. This leads to genomic instability and increased cancer susceptibility.

Would you like more specific information about any particular variant or associated condition?",,10.071994066238403,53,431,True,True,0.6153846153846154,"Perfect! I now have comprehensive information about BRCA1 pathogenic variants. Let me compile this information for you:

## Pathogenic Variants in BRCA1 and Associated Disease Conditions

Based on ClinVar database search, I found **13,961 pathogenic or likely pathogenic variants** in the BRCA1 gene (Gene ID: 672, located on chromosome 17q21.31).

### Primary Associated Disease Conditions:

1. **Breast-ovarian cancer, familial, susceptibility to, 1** (OMIM: 604370, MONDO:0011450)
2. **Hereditary cancer-predisposing syndrome** (MONDO:0015356)
3. **Hereditary breast ovarian cancer syndrome** (Orphanet: 145)

### Representative Pathogenic Variants Examples:

#### **Frameshift Variants (Loss of Function):**

1. **c.4978del (p.Glu1660fs)** - VCV004682075
   - Type: Deletion causing frameshift
   - Classification: Pathogenic
   - Disease: Hereditary cancer-predisposing syndrome

2. **c.3761_3770del (p.Lys1254fs)** - VCV004625605
   - Type: 10-base pair deletion causing frameshift
   - Classification: Pathogenic
   - Disease: Hereditary cancer-predisposing syndrome

3. **c.5047dup (p.Glu1683fs)** - VCV004539181
   - Type: Duplication causing frameshift
   - Classification: Pathogenic

4. **c.3457dup (p.Leu1153fs)** - VCV004533345
   - Classification: Pathogenic
   - Disease: Inherited breast cancer and ovarian cancer

#### **Nonsense Variants (Premature Stop Codons):**

5. **c.1507A>T (p.Lys503Ter)** - VCV004625641
   - Type: Single nucleotide variant creating stop codon
   - Classification: Pathogenic
   - Disease: Hereditary cancer-predisposing syndrome

6. **c.2704G>T (p.Glu902Ter)** - VCV004625385
   - Type: Nonsense mutation
   - Classification: Pathogenic
   - Disease: Hereditary cancer-predisposing syndrome

7. **c.3994G>T (p.Gly1332Ter)** - VCV004539187
   - Type: Nonsense mutation
   - Classification: Pathogenic

8. **c.237dup (p.Ser80Ter)** - VCV004542159
   - Type: Duplication leading to stop codon
   - Classification: Pathogenic

#### **Copy Number Variations:**

9. **GRCh37/hg19 17q21.31(chr17:41236314-41249306)x1** - VCV004682099
   - Type: Copy number loss (deletion)
   - Classification: Pathogenic

10. **GRCh37/hg19 17q21.31(chr17:41201138-41201211)x1** - VCV004535447
    - Type: Copy number loss
    - Classification: Pathogenic

#### **Complex Indels:**

11. **c.2954_2958delinsATA (p.Pro985fs)** - VCV004625631
    - Type: Deletion-insertion (Indel) causing frameshift
    - Classification: Pathogenic
    - Disease: Hereditary cancer-predisposing syndrome

12. **c.2386_2388delinsCC (p.Thr796fs)** - VCV004625501
    - Type: Indel causing frameshift
    - Classification: Pathogenic

### Key Clinical Implications:

**BRCA1** is a tumor suppressor gene that encodes a protein involved in:
- DNA repair (particularly double-strand break repair)
- Cell cycle regulation
- Transcriptional regulation
- Ubiquitination

**Cancer Risks Associated with BRCA1 Pathogenic Variants:**
- **Breast cancer**: 55-72% lifetime risk
- **Ovarian cancer**: 39-44% lifetime risk
- Also increased risk for: pancreatic cancer, prostate cancer (in males)

**Molecular Consequences:**
- Frameshift variants (most common pathogenic type)
- Nonsense mutations
- Large deletions/duplications
- Splice site variants
- Missense variants (some classified as uncertain significance)

The pathogenic variants in BRCA1 predominantly result in loss of protein function through truncation, frameshift, or deletion of critical functional domains, leading to compromised DNA repair capacity and increased cancer susceptibility.",,65.02657675743103,21,2339,42543,164427,"mcp__togomcp__search_uniprot_entity, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary, mcp__togomcp__ncbi_esummary, mcp__togomcp__run_sparql, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary","[{""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""BRCA1 human"", ""limit"": 5}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""BRCA1 AND human[organism]"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""BRCA1 AND pathogenic"", ""max_results"": 20}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""gene"", ""ids"": [""7157""]}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""clinvar"", ""ids"": [""4686632"", ""4686574"", ""4686571"", ""4686569"", ""4686568"", ""4686567"", ""4686566"", ""4686565"", ""4685439"", ""4685271""]}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX cvo: <http://purl.jp/bio/10/clinvar/>\n\nSELECT DISTINCT ?variant ?title ?classification ?condition\nWHERE {\n  ?variant rdf:type cvo:VariationArchiveType .\n  ?variant cvo:title ?title .\n  ?variant cvo:interpreted_record ?record .\n  ?record cvo:clinical_assertion ?assertion .\n  ?assertion cvo:classification ?classification .\n  ?assertion cvo:condition ?condition .\n  \n  FILTER(CONTAINS(LCASE(?title), \""brca1\""))\n  FILTER(CONTAINS(LCASE(?classification), \""pathogenic\""))\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""BRCA1[gene] AND (pathogenic[clinical significance] OR likely pathogenic[clinical significance])"", ""max_results"": 50}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""clinvar"", ""ids"": [""4686574"", ""4686566"", ""4682099"", ""4682075"", ""4625641"", ""4625631"", ""4625605"", ""4625576"", ""4625501"", ""4625451"", ""4625385"", ""4625305"", ""4625013"", ""4624991"", ""4542159"", ""4539187"", ""4539181"", ""4535447"", ""4533345"", ""4533111""]}}]",VALUABLE,"List of pathogenic BRCA1 variants with their associated diseases (breast cancer, ovarian cancer syndromes)","COMPLEX QUERY requiring variant-disease integration.

Databases/Resources: ClinVar, MedGen

Knowledge Required:
- Gene-based variant filtering via med2rdf:gene
- Disease association via dct:references → rdfs:seeAlso path
- Clinical significance property path
- VALUES pre-filtering for BRCA1 gene URI

Without proper knowledge: Cannot navigate variant-disease relationships correctly.

Verified in clinvar_exploration.md Patterns 1 and 2."
64,2026-02-01,Integration,What PDB structures are available for UniProt protein P38398?,True,False,False,0.14285714285714285,"I don't have access to real-time databases or the ability to query the PDB (Protein Data Bank) or UniProt directly. To find PDB structures for UniProt protein P38398, you would need to:

1. **Visit UniProt directly**: Go to https://www.uniprot.org/uniprotkb/P38398
2. **Check the ""Structure"" section**: This will list all associated PDB entries
3. **Or visit RCSB PDB**: Search for P38398 at https://www.rcsb.org

Alternatively, you can use the UniProt API or PDB API to programmatically retrieve this information.

Without access to current databases, I cannot tell you which specific PDB structures are available for this protein. The availability of structures changes over time as new structures are deposited.

If you let me know what protein P38398 corresponds to (the protein name), I might be able to provide some general context about whether structures are commonly available for that type of protein, but I cannot provide the specific PDB IDs without database access.",,6.958010196685791,52,245,True,True,0.7142857142857143,"Excellent! I found 34 PDB structures associated with UniProt protein P38398 (BRCA1). Here's a summary of the available structures:

## PDB Structures for UniProt P38398 (BRCA1)

**Total: 34 structures**

### Key Structural Categories:

**BRCT Domain Structures (majority):**
- **1jnx** - Crystal structure of the BRCT repeat region
- **1oqa** - Solution structure of the BRCT-c domain
- **1t15** - BRCT domains with phosphorylated Bach1 helicase peptide
- **1t29, 1t2u, 1t2v** - BRCT repeats with phosphorylated BACH1 peptides
- **1y98** - BRCT repeats bound to CtIP phosphopeptide
- **4y18, 4y2g** - BRCT domains with Abraxas phosphorylated peptides
- **4jlu, 4u4a** - BRCT with phospho-Abraxas
- **4ofb** - BRCT with nonphosphopeptide inhibitor
- **3coj** - BRCT with acetyl-CoA carboxylase 1 peptide
- **4ifi** - BRCT with BAAT peptide
- **4igk** - BRCT with ATRIP peptide
- **8rs8** - BRCTs with RIF1 phosphopeptide
- **9qpx** - BRCT tandem repeat with RNA polymerase II CTD peptide

**BRCT Mutant Structures:**
- **1n5o** - Cancer-causing BRCT missense mutation
- **2ing** - BRCT mutant M1775K
- **3pxa, 3pxb, 3pxc, 3pxd, 3pxe** - Various BRCT missense substitutions
- **3k15, 3k16** - BRCT D1840T mutant

**RING Domain Structures:**
- **1jm7** - Solution structure of BRCA1/BARD1 RING-domain heterodimer

**Nucleosome Complex Structures (Cryo-EM):**
- **7jzv** - BRCA1-UbcH5c/BARD1 E3-E2 module bound to nucleosome
- **7lyb** - Human nucleosome core particle with BRCA1-BARD1-UbcH5c
- **8grq** - BRCA1/BARD1 bound to H2AK127-UbcH5c-Ub nucleosome

**Other Domains:**
- **7k3s** - Solution NMR structure of coiled-coil BRCA1-PALB2 heterodimer
- **6g2i** - Filament of acetyl-CoA carboxylase and BRCT domains (5.9 Å)

These structures cover various functional domains and interactions of BRCA1, particularly the BRCT domains involved in phosphopeptide recognition, the RING domain involved in E3 ubiquitin ligase activity, and complex assemblies with nucleosomes and partner proteins.",,45.589207887649536,21,1759,2942,106249,"mcp__togomcp__run_sparql, mcp__togomcp__search_uniprot_entity, mcp__togomcp__run_sparql, mcp__togomcp__search_pdb_entity","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?pdbId ?resolution ?method ?chains\nWHERE {\n  <http://purl.uniprot.org/uniprot/P38398> up:annotation ?annotation .\n  ?annotation a up:Structure_Annotation ;\n                rdfs:seeAlso ?pdb .\n  ?pdb up:database <http://purl.uniprot.org/database/PDB> ;\n       rdfs:comment ?pdbId .\n  OPTIONAL { ?pdb up:resolution ?resolution }\n  OPTIONAL { ?pdb up:method ?method }\n  OPTIONAL { ?pdb up:chains ?chains }\n}\nORDER BY ?pdbId\n""}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""P38398"", ""limit"": 5}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX pdbx: <http://pdbj.org/schema/pdbx-v50.owl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?pdb ?title ?method ?resolution\nWHERE {\n  ?entity a pdbx:entity_src_genCategory ;\n          pdbx:entity_src_gen.pdbx_gene_src_common_name ?protein .\n  ?entity pdbx:entity_src_gen.pdbx_src_id \""P38398\"" .\n  ?entry a pdbx:datablock ;\n         pdbx:has_entity_src_genCategory ?entity .\n  BIND(REPLACE(STR(?entry), \"".*/(\\\\w+)$\"", \""$1\"") AS ?pdb)\n  OPTIONAL {\n    ?entry pdbx:has_struct_keywordsCategory ?keywords .\n    ?keywords pdbx:struct_keywords.pdbx_text ?title .\n  }\n  OPTIONAL {\n    ?entry pdbx:has_exptlCategory ?exptl .\n    ?exptl pdbx:exptl.method ?method .\n  }\n  OPTIONAL {\n    ?entry pdbx:has_reflnsCategory ?reflns .\n    ?reflns pdbx:reflns.d_resolution_high ?resolution .\n  }\n}\nLIMIT 100\n""}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""P38398 BRCA1"", ""limit"": 50}}]",CRITICAL,"20+ PDB structures for BRCA1 (P38398) including 4Y2G, 4Y18, 7JZV","SIMPLE QUERY - Straightforward ID conversion.

Method: togoid_convertId(ids='P38398', route='uniprot,pdb')

Demonstrates when basic cross-reference tools suffice.

Verified in uniprot_exploration.md simple queries section."
65,2026-02-01,Completeness,What is the distribution of BRCA1 variant types in ClinVar?,True,False,False,0.4,"I don't have access to real-time ClinVar database information, so I cannot provide you with current statistics on BRCA1 variant distributions. However, I can share some general knowledge about the types of variants typically found in BRCA1:

## Common BRCA1 Variant Types:

1. **Missense variants** - Single nucleotide changes resulting in amino acid substitutions

2. **Frameshift variants** - Small insertions or deletions that shift the reading frame, often leading to truncated proteins

3. **Nonsense variants** - Point mutations creating premature stop codons

4. **Splice site variants** - Mutations affecting RNA splicing sites

5. **Large deletions/duplications** - Copy number variations affecting one or more exons

6. **Synonymous variants** - Changes that don't alter amino acids (usually benign)

## Clinical Significance Distribution:
BRCA1 variants in ClinVar are typically classified as:
- Pathogenic/Likely Pathogenic
- Benign/Likely Benign
- Variants of Uncertain Significance (VUS)

**To get current distribution data**, you would need to:
- Query the ClinVar database directly at ncbi.nlm.nih.gov/clinvar
- Search for ""BRCA1"" and filter by variant type
- Download the latest ClinVar release files for statistical analysis

The distribution can change over time as new variants are reported and classifications are updated based on new evidence.",,8.206447839736938,54,338,True,False,0.4,"Based on my analysis of the ClinVar database, here's the distribution of BRCA1 variant types:

## Distribution of BRCA1 Variant Types in ClinVar

**Total BRCA1 variants in ClinVar: 15,663**

| Variant Type | Count | Percentage |
|---|---|---|
| **Single nucleotide variant** | 11,361 | 72.5% |
| **Deletion** | 2,802 | 17.9% |
| **Duplication** | 1,100 | 7.0% |
| **Insertion** | 575 | 3.7% |
| **Indel** | 285 | 1.8% |
| **Copy number loss** | 8 | 0.05% |

### Key Findings:

1. **Single nucleotide variants (SNVs)** are by far the most common type, representing nearly three-quarters of all BRCA1 variants in ClinVar. These include:
   - Missense variants (amino acid substitutions)
   - Nonsense variants (premature stop codons)
   - Synonymous variants (silent mutations)
   - Splice site variants

2. **Deletions** are the second most common, accounting for about 18% of variants. These range from single nucleotide deletions to larger deletions affecting multiple exons.

3. **Duplications, Insertions, and Indels** together represent about 12.5% of variants, involving the addition or complex rearrangement of genetic material.

4. **Copy number losses** (large deletions) are relatively rare, representing only a tiny fraction of variants.

This distribution reflects the types of mutations that occur in BRCA1 and are clinically relevant for hereditary breast and ovarian cancer susceptibility. The predominance of SNVs is typical for most genes, as point mutations are the most common type of genetic variation.",,53.19083380699158,21,1735,35267,198281,"mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary, mcp__togomcp__run_sparql, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch","[{""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""BRCA1[gene]"", ""max_results"": 100}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""clinvar"", ""ids"": [""4686574"", ""4686566"", ""4685876"", ""4684220"", ""4682099"", ""4682075"", ""4625777"", ""4625766"", ""4625758"", ""4625747"", ""4625730"", ""4625659"", ""4625641"", ""4625631"", ""4625605"", ""4625581"", ""4625576"", ""4625534"", ""4625529"", ""4625516"", ""4625505"", ""4625501"", ""4625458"", ""4625451"", ""4625448"", ""4625434"", ""4625431"", ""4625385"", ""4625363"", ""4625349""]}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""\nPREFIX cvo: <http://purl.jp/bio/10/clinvar/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?variantType (COUNT(?variant) AS ?count)\nWHERE {\n  ?variant cvo:interpreted_record ?record .\n  ?record cvo:gene ?gene .\n  ?gene rdfs:label \""BRCA1\"" .\n  ?variant cvo:variant_type ?variantType .\n}\nGROUP BY ?variantType\nORDER BY DESC(?count)\n""}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""BRCA1[gene] AND \""single nucleotide variant\""[variant type]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""BRCA1[gene] AND \""deletion\""[variant type]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""BRCA1[gene] AND \""insertion\""[variant type]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""BRCA1[gene] AND \""duplication\""[variant type]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""BRCA1[gene] AND \""indel\""[variant type]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""BRCA1[gene] AND \""copy number loss\""[variant type]"", ""max_results"": 1}}]",CRITICAL,"SNV (~60%), deletions (~25%), duplications (~10%), others (~5%), totaling ~15,000 BRCA1 variants","COMPLEX QUERY requiring aggregation knowledge.

Databases/Resources: ClinVar

Knowledge Required:
- bif:contains for gene name search
- variation_type property for classification
- GROUP BY for aggregation
- record_status 'current' filter

Without proper knowledge: Cannot aggregate correctly or inefficient without bif:contains.

Verified in clinvar_exploration.md Pattern 4 (Gene-Specific Variant Counts)."
66,2026-02-01,Completeness,How many transport reactions are recorded in the Rhea database?,True,False,True,1.0,"I don't have access to the specific current number of transport reactions in the Rhea database. Rhea is a comprehensive database of biochemical reactions that includes various types of reactions, including transport reactions, but the exact count would depend on the version and release date of the database.

The number of reactions in Rhea is constantly growing as new reactions are curated and added. To get the accurate current number of transport reactions, you would need to:

1. Visit the Rhea database directly (https://www.rhea-db.org/)
2. Check their latest statistics or release notes
3. Use their search functionality to filter for transport reactions specifically

If you need this information for a specific purpose, I'd recommend checking the official Rhea database website or their latest publication for the most up-to-date statistics.",,6.821886777877808,50,178,True,True,1.0,"Perfect! Based on my queries of the Rhea database, I can now provide you with a comprehensive answer.

## Answer

According to the Rhea database, there are **5,984 transport reactions** recorded.

These are reactions that involve the movement of molecules across biological membranes or between cellular compartments, indicated in Rhea by the notation ""(in)"" and ""(out)"" in the reaction equations to show the different sides of the membrane. The database explicitly marks these reactions with an `isTransport` property set to `true`.

Examples of transport reactions in Rhea include:
- **RHEA:20624**: ATP + H2O + Zn(2+)(in) ⇌ ADP + H(+) + phosphate + Zn(2+)(out) - zinc transport
- **RHEA:20835**: ATP + guanine(out) + H2O ⇌ ADP + guanine(in) + H(+) + phosphate - guanine transport
- **RHEA:20855**: ATP + H(+)(in) + H2O ⇌ ADP + 2 H(+)(out) + phosphate - proton transport

Note that Rhea records reactions in multiple forms (undirected, left-to-right, right-to-left, and bidirectional), so the total count of 5,984 includes all these directional variants of the transport reactions.",,124.61341595649719,61,3730,18307,717625,"mcp__togomcp__search_rhea_entity, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__search_rhea_entity, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, WebSearch, mcp__togomcp__search_rhea_entity, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""transport"", ""limit"": 100}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?count)\nWHERE {\n  ?reaction a rh:Reaction .\n  ?reaction rdfs:label ?label .\n  FILTER(CONTAINS(LCASE(?label), \""transport\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?count)\nWHERE {\n  ?reaction a rh:Reaction .\n  ?reaction rh:equation ?equation .\n  FILTER(REGEX(?equation, \""\\\\(in\\\\)|\\\\(out\\\\)\"", \""i\""))\n}\n""}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""(in) (out)"", ""limit"": 1000}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX up: <http://purl.uniprot.org/core/>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?transportCount)\nWHERE {\n  ?reaction a rh:Reaction ;\n            rh:ec ?ec .\n  ?ec rdfs:subClassOf* <http://purl.uniprot.org/enzyme/7.-.-.-> .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?count)\nWHERE {\n  ?reaction a rh:Reaction ;\n            rh:ec ?ec .\n  FILTER(STRSTARTS(STR(?ec), \""http://purl.uniprot.org/enzyme/7\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?type (COUNT(?reaction) AS ?count)\nWHERE {\n  ?reaction a ?type .\n  FILTER(STRSTARTS(STR(?type), \""http://rdf.rhea-db.org/\""))\n}\nGROUP BY ?type\nORDER BY DESC(?count)\nLIMIT 20\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT DISTINCT ?type\nWHERE {\n  ?s a ?type .\n}\nLIMIT 10\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nSELECT DISTINCT ?type\nWHERE {\n  ?s a ?type .\n  FILTER(CONTAINS(STR(?type), \""rhea\""))\n}\nLIMIT 20\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT (COUNT(*) AS ?count)\nWHERE {\n  ?s ?p ?o .\n  FILTER(CONTAINS(STR(?o), \""(out)\"") || CONTAINS(STR(?o), \""(in)\""))\n}\n""}}, {""name"": ""WebSearch"", ""input"": {""query"": ""Rhea database transport reactions count statistics""}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""*"", ""limit"": 100}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?count)\nWHERE {\n  ?reaction rh:equation ?equation .\n  FILTER(CONTAINS(?equation, \""(in)\"") && CONTAINS(?equation, \""(out)\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT ?reaction ?equation\nWHERE {\n  ?reaction rh:equation ?equation .\n  FILTER(CONTAINS(?equation, \""(in)\"") && CONTAINS(?equation, \""(out)\""))\n}\nLIMIT 10\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?allTransport)\n       (COUNT(DISTINCT ?master) AS ?masterTransport)\nWHERE {\n  ?reaction rh:equation ?equation .\n  FILTER(CONTAINS(?equation, \""(in)\"") && CONTAINS(?equation, \""(out)\""))\n  OPTIONAL { ?reaction rh:isTransport \""true\""^^<http://www.w3.org/2001/XMLSchema#boolean> }\n  OPTIONAL { ?reaction rh:accession ?master }\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT DISTINCT ?property\nWHERE {\n  ?reaction rh:equation ?equation .\n  FILTER(CONTAINS(?equation, \""(in)\"") && CONTAINS(?equation, \""(out)\""))\n  ?reaction ?property ?value .\n  FILTER(STRSTARTS(STR(?property), \""http://rdf.rhea-db.org/\""))\n}\nLIMIT 30\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?transportReactions)\nWHERE {\n  ?reaction rh:isTransport \""true\""^^<http://www.w3.org/2001/XMLSchema#boolean> .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?count) ?type\nWHERE {\n  ?reaction rh:isTransport \""true\""^^<http://www.w3.org/2001/XMLSchema#boolean> .\n  ?reaction rdf:type ?type .\n  FILTER(?type = rh:Reaction || ?type = rh:BidirectionalReaction || ?type = rh:DirectionalReaction)\n}\nGROUP BY ?type\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT ?reaction ?equation\nWHERE {\n  ?reaction rh:isTransport \""true\""^^<http://www.w3.org/2001/XMLSchema#boolean> .\n  ?reaction rh:equation ?equation .\n}\nLIMIT 15\n""}}]",CRITICAL,"1,496 transport reactions","SIMPLE QUERY - Straightforward count with transport filter.

Method: Simple SPARQL COUNT with rhea:isTransport 1 filter

Demonstrates a straightforward completeness query.

Verified in rhea_exploration.md (Dataset Size section)."
67,2026-02-01,Specificity,Which GO molecular functions have enzyme classification (EC) numbers?,True,True,True,0.7777777777777778,"GO molecular functions that have EC numbers are those describing **enzymatic activities**. These are typically found in the ""catalytic activity"" branch of the Molecular Function ontology.

Examples of GO molecular function categories with EC numbers include:

1. **Oxidoreductases** (EC 1.x.x.x) - e.g., ""alcohol dehydrogenase activity""
2. **Transferases** (EC 2.x.x.x) - e.g., ""protein kinase activity"", ""methyltransferase activity""
3. **Hydrolases** (EC 3.x.x.x) - e.g., ""peptidase activity"", ""ATPase activity""
4. **Lyases** (EC 4.x.x.x) - e.g., ""carbonate dehydratase activity""
5. **Isomerases** (EC 5.x.x.x) - e.g., ""protein disulfide isomerase activity""
6. **Ligases** (EC 6.x.x.x) - e.g., ""DNA ligase activity""
7. **Translocases** (EC 7.x.x.x) - e.g., certain transporter activities

The EC number system classifies enzymes based on the chemical reactions they catalyze, and GO Molecular Function terms for specific enzymatic activities are often cross-referenced with their corresponding EC numbers. Not all GO molecular functions have EC numbers - only those that describe catalytic/enzymatic activities. Other molecular functions like ""binding"" activities, ""structural molecule activity"", or ""receptor activity"" generally do not have EC numbers.",,7.954806089401245,49,375,True,True,0.8888888888888888,"Excellent! I can see the data now. The results show many GO molecular function terms with their associated EC numbers. Let me analyze this data to provide you with a comprehensive answer about the types of GO molecular functions that have EC numbers.

Based on the SPARQL query results from the Gene Ontology database, **many GO molecular function terms have associated enzyme classification (EC) numbers**. Here's what I found:

## Major Categories with EC Numbers:

1. **Oxidoreductases (EC 1.-.-.-)** - Enzymes catalyzing oxidation-reduction reactions
   - Examples: aldehyde dehydrogenase (EC:1.2.1.3), glucose-6-phosphate dehydrogenase (EC:1.1.1.49), cytochrome-c oxidase (EC:7.1.1.9)
   - Includes peroxidases, dehydrogenases, oxidases, and reductases

2. **Transferases (EC 2.-.-.-)** - Enzymes transferring functional groups
   - Examples: glutathione transferase (EC:2.5.1.18), protein serine/threonine kinase (EC:2.7.11.-), protein tyrosine kinase (EC:2.7.10.-)
   - Includes kinases, acetyltransferases, glycosyltransferases

3. **Hydrolases (EC 3.-.-.-)** - Enzymes catalyzing hydrolysis reactions
   - Examples: alpha-amylase (EC:3.2.1.1), beta-galactosidase (EC:3.2.1.23), serine-type endopeptidase (EC:3.4.21.-)
   - Includes peptidases, glycosidases, phosphatases, sulfatases

4. **Lyases (EC 4.-.-.-)** - Enzymes cleaving bonds
   - Examples: pyruvate decarboxylase (EC:4.1.1.1), adenylate cyclase (EC:4.6.1.1)

5. **Isomerases (EC 5.-.-.-)** - Enzymes catalyzing isomerization
   - Examples: peptidyl-prolyl cis-trans isomerase (EC:5.2.1.8), protein disulfide isomerase (EC:5.3.4.1)
   - Includes macromolecular conformation isomerases (EC:5.6.-.-)

6. **Ligases (EC 6.-.-.-)** - Enzymes forming bonds
   - Examples: glutamate-cysteine ligase (EC:6.3.2.2), ubiquitin activating enzyme (EC:6.2.1.45)

7. **Translocases (EC 7.-.-.-)** - Enzymes catalyzing translocation
   - Examples: transporter activity (EC:7.-.-.-), ATPase-coupled transmembrane transporter (EC:7.2.2.-)

## Key Observations:

- **Broad coverage**: EC numbers are associated with GO terms ranging from very specific enzyme activities (e.g., EC:1.1.1.49 for glucose-6-phosphate dehydrogenase) to general functional categories (e.g., EC:1.-.-.- for oxidoreductase activity)

- **Clinical significance**: Many terms with EC numbers are involved in genetic diseases (e.g., glucosylceramidase - EC:3.2.1.45, associated with Gaucher disease)

- **Incomplete EC numbers**: Some GO terms have partial EC numbers with dashes (e.g., EC:3.4.21.- for serine-type endopeptidase), indicating the enzyme class is known but specific sub-classification is incomplete

Essentially, **most enzymatic activities in GO have EC number cross-references**, making it easy to link between the two classification systems.",,63.21331310272217,31,2097,33336,177272,"mcp__ols__search, mcp__ols__fetch, mcp__ols__fetch, mcp__ols__fetch, mcp__ols__fetch, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__ols__search"", ""input"": {""query"": ""GO molecular function enzyme activity EC""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0004855""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0004742""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0003917""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0031071""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""go"", ""sparql_query"": ""PREFIX obo: <http://purl.obolibrary.org/obo/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX oboInOwl: <http://www.geneontology.org/formats/oboInOwl#>\n\nSELECT DISTINCT ?goterm ?label ?ec\nWHERE {\n  ?goterm rdfs:subClassOf* obo:GO_0003674 .\n  ?goterm rdfs:label ?label .\n  ?goterm oboInOwl:hasDbXref ?ec .\n  FILTER(STRSTARTS(STR(?ec), \""EC:\""))\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""go"", ""sparql_query"": ""PREFIX obo: <http://purl.obolibrary.org/obo/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX oboInOwl: <http://www.geneontology.org/formats/oboInOwl#>\n\nSELECT (COUNT(DISTINCT ?goterm) as ?count)\nWHERE {\n  ?goterm rdfs:subClassOf* obo:GO_0003674 .\n  ?goterm oboInOwl:hasDbXref ?ec .\n  FILTER(STRSTARTS(STR(?ec), \""EC:\""))\n}""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""go"", ""sparql_query"": ""PREFIX obo: <http://purl.obolibrary.org/obo/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX oboInOwl: <http://www.geneontology.org/formats/oboInOwl#>\n\nSELECT DISTINCT ?goterm ?label ?ec\nWHERE {\n  ?goterm rdfs:subClassOf* obo:GO_0003674 .\n  ?goterm rdfs:label ?label .\n  ?goterm oboInOwl:hasDbXref ?ec .\n  FILTER(STRSTARTS(STR(?ec), \""EC:\""))\n}\nLIMIT 500""}}]",VALUABLE,"GO molecular functions with EC cross-references, such as kinase activities and transferase activities","COMPLEX QUERY requiring cross-reference knowledge.

Databases/Resources: GO

Knowledge Required:
- hasDbXref property for external links
- STRSTARTS filter for 'EC:' prefix
- STR() for namespace filtering to molecular_function
- FROM clause for consistent results

Without proper knowledge: Cannot identify EC cross-references correctly.

Verified in go_exploration.md Pattern 7 (Cross-Reference Query)."
68,2026-02-01,Specificity,What is the definition of the GO term for 'protein kinase activity'?,True,True,True,0.8571428571428571,"The GO (Gene Ontology) term for 'protein kinase activity' is **GO:0004672**.

**Definition:** Catalysis of the phosphorylation of an amino acid residue in a protein, usually according to the reaction: a protein + ATP = a phosphoprotein + ADP.

This is a molecular function term that describes the catalytic activity of protein kinases - enzymes that transfer phosphate groups from ATP (or other nucleoside triphosphates) to specific amino acid residues (typically serine, threonine, or tyrosine) on target proteins. This phosphorylation is a key post-translational modification used in cellular signaling and regulation.",,3.8338561058044434,54,154,True,True,0.7142857142857143,"The GO term for **'protein kinase activity'** is **GO:0004672**.

**Definition:** Catalysis of the phosphorylation of an amino acid residue in a protein, usually according to the reaction: a protein + ATP = a phosphoprotein + ADP.

This is a molecular function term in the Gene Ontology that describes the enzymatic activity of protein kinases, which transfer phosphate groups from ATP to specific amino acid residues (typically serine, threonine, or tyrosine) in target proteins.",,16.34862494468689,14,305,1953,79952,"mcp__ols__search, mcp__ols__fetch","[{""name"": ""mcp__ols__search"", ""input"": {""query"": ""protein kinase activity""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0004672""}}]",VALUABLE,Definition of GO:0004672 describing protein kinase catalytic activity,"SIMPLE QUERY - Straightforward term definition lookup.

Method: OLS4 fetch for GO:0004672

Demonstrates when basic ontology lookup tools suffice.

Verified in go_exploration.md simple queries section."
69,2026-02-01,Currency,What are the largest multi-protein complexes that have been structurally characterized?,True,True,False,0.3076923076923077,"Some of the largest multi-protein complexes that have been structurally characterized include:

## **Ribosome (~2.5-4.5 MDa)**
One of the earliest and most extensively studied massive complexes, consisting of ribosomal RNA and dozens of proteins. Both prokaryotic (70S, ~2.5 MDa) and eukaryotic (80S, ~4.2 MDa) ribosomes have been solved at high resolution.

## **Nuclear Pore Complex (~110-120 MDa)**
Among the largest, with approximately 500-1000 protein subunits (30+ different types). Complete structural characterization has been challenging, but significant progress has been made using cryo-ET and integrative modeling approaches.

## **Proteasome (26S, ~2.5 MDa)**
The protein degradation machinery, consisting of the 20S core particle and 19S regulatory particles, has been extensively characterized.

## **Vault Particles (~13 MDa)**
Large ribonucleoprotein complexes with unclear function, consisting of multiple copies of major vault protein (MVP) and other components.

## **Pyruvate Dehydrogenase Complex (~10 MDa in mammals)**
A massive metabolic enzyme complex with multiple copies of three different enzymes.

## **GroEL-GroES Chaperonin (~1 MDa)**
A well-characterized protein folding machine.

## **Viral Capsids**
Some of the largest include:
- **Mimivirus capsid** (~1 MDa for the capsid proteins alone)
- **Bacteriophages** like T4 (~200 MDa complete virus)

Recent advances in **cryo-electron microscopy (cryo-EM)** and **cryo-electron tomography (cryo-ET)** have been crucial for solving these enormous structures.",,10.4996657371521,54,433,True,False,0.38461538461538464,"Based on the search results and general knowledge of structural biology, here are some of the **largest multi-protein complexes that have been structurally characterized**:

## Major Large Protein Complexes

### 1. **Ribosomes** (Most abundant)
- **70S Ribosome** (bacterial): ~2.5 MDa, contains ~50-55 proteins plus rRNA
- **80S Ribosome** (eukaryotic): ~3-4 MDa, contains ~80 proteins plus rRNA
- The ribosome is one of the most extensively studied large complexes, with over 9,000 structures in the PDB
- Examples include E. coli 70S ribosomes, human 80S ribosomes, and various functional states

### 2. **Virus Capsids** (Largest by far)
- Can contain hundreds to thousands of protein subunits
- Examples include:
  - **Adenovirus**: ~150 MDa
  - **HIV capsid**: ~1,000+ proteins forming cone-shaped structure
  - **Bacteriophages** like T4: massive tail and head assemblies
- Over 5,600 viral capsid structures available

### 3. **Proteasome**
- **26S Proteasome**: ~2.5 MDa
  - Core 20S particle (~700 kDa) + two 19S regulatory particles
  - Contains ~60+ subunits total
- 3,900+ proteasome structures in PDB

### 4. **Other Notable Large Complexes**

- **Nuclear pore complex (NPC)**: ~110 MDa (one of the largest), ~1,000 proteins
- **Vault particles**: ~13 MDa, 78 protein copies
- **GroEL/GroES chaperonin**: ~1 MDa, 14+7 subunits
- **Photosystem complexes**: Several hundred kDa
- **Spliceosome**: ~4 MDa in active form
- **Bacterial flagellar motor**: ~100 MDa
- **Clathrin-coated vesicles**: Can exceed 50 MDa

The **virus capsids** hold the record for largest symmetric protein assemblies, while complexes like the **nuclear pore complex** and **bacterial flagellar motor** represent the largest asymmetric multi-protein machines structurally characterized, primarily through cryo-electron microscopy (cryo-EM) which has revolutionized the field since the mid-2010s.",,29.709975004196167,14,1009,2813,78733,"mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity","[{""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""large protein complex ribosome virus capsid proteasome"", ""limit"": 30}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""ribosome"", ""limit"": 20}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""virus capsid"", ""limit"": 20}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""proteasome"", ""limit"": 20}}]",VALUABLE,"Large complexes such as Trypanosoma brucei mitoribosome (125 proteins), human ribosome complexes (80+ proteins)","COMPLEX QUERY requiring multi-chain aggregation.

Databases/Resources: PDB

Knowledge Required:
- struct_ref category for UniProt cross-references
- COUNT DISTINCT for unique protein components
- HAVING clause for minimum threshold
- GROUP BY for per-structure aggregation

Without proper knowledge: Cannot count distinct protein components per structure.

Verified in pdb_exploration.md Pattern 8 (Multi-Chain Structure Query)."
70,2026-02-01,Currency,What compounds have been tested against G protein-coupled receptors as antagonists?,True,True,False,0.4444444444444444,"# Compounds Tested as GPCR Antagonists

G protein-coupled receptors (GPCRs) are one of the largest and most important drug target families. Numerous compounds have been tested as GPCR antagonists across different receptor subtypes. Here are major categories:

## **Adrenergic Receptor Antagonists**
- **Beta-blockers**: Propranolol, atenolol, metoprolol, carvedilol
- **Alpha-blockers**: Prazosin, doxazosin, phentolamine, tamsulosin

## **Histamine Receptor Antagonists**
- **H1 antagonists**: Diphenhydramine, loratadine, cetirizine, fexofenadine
- **H2 antagonists**: Cimetidine, ranitidine, famotidine

## **Dopamine Receptor Antagonists**
- Haloperidol, chlorpromazine, risperidone, olanzapine, domperidone

## **Serotonin Receptor Antagonists**
- Ondansetron, granisetron (5-HT3)
- Ketanserin (5-HT2A)
- Clozapine (multiple subtypes)

## **Muscarinic Receptor Antagonists**
- Atropine, scopolamine, ipratropium, tiotropium

## **Angiotensin Receptor Antagonists (ARBs)**
- Losartan, valsartan, irbesartan, candesartan

## **Opioid Receptor Antagonists**
- Naloxone, naltrexone, methylnaltrexone

## **Chemokine Receptor Antagonists**
- Maraviroc (CCR5)
- Plerixafor (CXCR4)

## **Other Notable GPCR Antagonists**
- **Neurokinin**: Aprepitant (NK1)
- **Leukotriene**: Montelukast (CysLT1)
- **Endothelin**: Bosentan (ETA/ETB)

This represents a fraction of tested compounds, as thousands have been evaluated in research and drug development programs.",,9.405345916748047,53,535,True,False,0.4444444444444444,"Based on my search through the ChEMBL database, I can provide you with information about compounds that have been tested as antagonists against G protein-coupled receptors (GPCRs). Here are examples across different GPCR families:

## **Adrenergic Receptor Antagonists (Beta-blockers and Alpha-blockers)**

**Beta-adrenergic antagonists:**
- **Propranolol** (CHEMBL27) - Non-selective beta-blocker
- **Atenolol** (CHEMBL24) - Selective beta-1 blocker
- **Carvedilol** (CHEMBL723) - Non-selective beta-blocker with alpha-1 blocking activity

**Alpha-adrenergic antagonists:**
- **Prazosin** (CHEMBL2) - Alpha-1 adrenergic receptor antagonist

## **Dopamine Receptor Antagonists**

- **Haloperidol** (typical antipsychotic) - Primarily D2 receptor antagonist

## **Serotonin (5-HT) Receptor Antagonists**

- **Ondansetron** (CHEMBL46) - 5-HT3 receptor antagonist (antiemetic)

## **Histamine Receptor Antagonists**

- **Ranitidine** (CHEMBL1790041) - H2 receptor antagonist (acid reducer)
- **Cetirizine** (CHEMBL1000) - H1 receptor antagonist (antihistamine)

## **Opioid Receptor Antagonists**

- **Naloxone** - Opioid receptor antagonist (reverses opioid overdose)

## **Angiotensin Receptor Antagonists**

- **Losartan** - AT1 receptor antagonist (blood pressure medication)

## **Muscarinic Receptor Antagonists**

- **Atropine** - Non-selective muscarinic acetylcholine receptor antagonist

These compounds represent just a fraction of the thousands of GPCR antagonists that have been tested. The ChEMBL database contains over 2,600 different GPCR targets with associated bioactivity data for numerous compounds tested as antagonists. GPCRs represent the largest family of drug targets, with approximately 34% of all FDA-approved drugs targeting these receptors.

Would you like me to search for antagonists of a specific GPCR subfamily or provide more detailed information about any of these compounds?",,95.68405413627625,46,2901,6904,230215,"mcp__togomcp__search_chembl_target, mcp__togomcp__run_sparql, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule","[{""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""G protein-coupled receptor"", ""limit"": 20}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?molecule ?molname ?target ?targetname ?activity_type ?value\nWHERE {\n  ?assay chembl:hasTarget ?target .\n  ?target a chembl:SingleProtein .\n  ?target chembl:targetType \""SINGLE PROTEIN\"" .\n  ?target chembl:organismName \""Homo sapiens\"" .\n  ?target chembl:preferredName ?targetname .\n  \n  FILTER(CONTAINS(LCASE(STR(?targetname)), \""receptor\"") && \n         (CONTAINS(LCASE(STR(?targetname)), \""gpcr\"") || \n          CONTAINS(LCASE(STR(?targetname)), \""g protein\"") ||\n          CONTAINS(LCASE(STR(?targetname)), \""adrenergic\"") ||\n          CONTAINS(LCASE(STR(?targetname)), \""dopamine\"") ||\n          CONTAINS(LCASE(STR(?targetname)), \""serotonin\"")))\n  \n  ?activity chembl:hasAssay ?assay .\n  ?activity chembl:hasMolecule ?molecule .\n  ?activity chembl:standardType ?activity_type .\n  ?activity chembl:standardValue ?value .\n  \n  FILTER(CONTAINS(LCASE(STR(?activity_type)), \""antagonist\"") || \n         CONTAINS(LCASE(STR(?activity_type)), \""ki\"") ||\n         CONTAINS(LCASE(STR(?activity_type)), \""ic50\""))\n  \n  OPTIONAL { ?molecule chembl:preferredCompoundName ?molname }\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""adrenergic receptor antagonist"", ""limit"": 10}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""propranolol"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""atenolol"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""prazosin"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""haloperidol"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""losartan"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""ranitidine"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""dopamine receptor"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""serotonin receptor"", ""limit"": 5}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?molname ?targetname\nWHERE {\n  ?molecule a chembl:SmallMolecule ;\n            chembl:preferredCompoundName ?molname .\n  \n  ?activity chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:type \""Antagonist\"" .\n  \n  ?assay chembl:hasTarget ?target .\n  ?target chembl:preferredName ?targetname .\n  \n  FILTER(CONTAINS(LCASE(?targetname), \""receptor\""))\n}\nLIMIT 50""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?molname ?targetname ?relation\nWHERE {\n  ?molecule a chembl:SmallMolecule ;\n            chembl:preferredCompoundName ?molname .\n  \n  ?activity chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:standardRelation ?relation .\n  \n  ?assay chembl:hasTarget ?target .\n  ?target a chembl:SingleProtein ;\n          chembl:preferredName ?targetname .\n  \n  FILTER(CONTAINS(LCASE(?targetname), \""adrenergic\"") || \n         CONTAINS(LCASE(?targetname), \""dopamine\"") ||\n         CONTAINS(LCASE(?targetname), \""serotonin\"") ||\n         CONTAINS(LCASE(?targetname), \""histamine\""))\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""atropine"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""ondansetron"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""naloxone"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""cetirizine"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""carvedilol"", ""limit"": 5}}]",VALUABLE,List of GPCR antagonist compounds from ChEMBL clinical development pipeline,"COMPLEX QUERY requiring mechanism filtering.

Databases/Resources: ChEMBL

Knowledge Required:
- DrugMechanism entity for action type
- mechanismActionType = 'ANTAGONIST' filter
- bif:contains for 'receptor' in target name
- Target type and organism filtering

Without proper knowledge: Cannot navigate DrugMechanism correctly or filter targets.

Verified in chembl_exploration.md Pattern 5."
71,2026-02-01,Precision,What is the resolution of the best structure for the human p53 DNA-binding domain?,True,True,True,0.6666666666666666,"The best resolution structure of the human p53 DNA-binding domain is approximately **1.3 Å** (angstroms).

This high-resolution structure (PDB ID: 2FEJ) was determined by X-ray crystallography and represents one of the highest quality structures available for this domain. The p53 DNA-binding domain (approximately residues 94-292) is the most frequently mutated region in human cancers, making high-resolution structural information particularly valuable for understanding cancer-related mutations.

There are many structures of the p53 DNA-binding domain in the PDB, both alone and in complex with DNA, but the ~1.3 Å resolution structures represent among the best in terms of resolution quality.",,5.314584016799927,56,162,True,True,0.6666666666666666,"Based on the PDB search results and the literature, I can see several high-resolution structures. The structure **2PCX** is specifically noted as ""Crystal structure of p53DBD(R282Q) at **1.54-angstrom Resolution**"" which appears to be one of the highest resolution structures for the human p53 DNA-binding domain.

According to the PDB database search, the best resolution structure for the human p53 DNA-binding domain is **PDB ID: 2PCX** with a resolution of **1.54 Å**. This structure contains the R282Q mutant of the p53 DNA-binding domain (core domain).

For wild-type p53 DNA-binding domain, structure **1UOL** (the mutant M133L/V203A/N239Y/N268D which is used to stabilize the core domain) is also reported at **1.9 Å resolution**.

The 1.54 Å resolution of 2PCX represents an exceptionally high-resolution structure for this important tumor suppressor protein domain, allowing detailed visualization of the protein's atomic structure and interactions.",,56.30714702606201,40,1953,7726,251286,"mcp__togomcp__search_pdb_entity, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata","[{""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""human p53 DNA-binding domain"", ""limit"": 20}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX PDBo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT ?pdbid ?resolution ?method ?title\nWHERE {\n  VALUES ?pdbid { \""2PCX\"" \""2XWR\"" \""2OCJ\"" \""1UOL\"" \""3TS8\"" \""4QO1\"" }\n  \n  ?entry a PDBo:datablock ;\n         PDBo:datablockName ?pdbid ;\n         PDBo:has_reflnsCategory ?reflns ;\n         PDBo:has_struct_keywordsCategory ?keywords .\n  \n  ?reflns PDBo:has_reflns ?reflns_data .\n  ?reflns_data PDBo:reflns.d_resolution_high ?resolution .\n  \n  ?keywords PDBo:has_struct_keywords ?kw_data .\n  ?kw_data PDBo:struct_keywords.pdbx_keywords ?title .\n  \n  OPTIONAL {\n    ?entry PDBo:has_exptlCategory ?exptl .\n    ?exptl PDBo:has_exptl ?exptl_data .\n    ?exptl_data PDBo:exptl.method ?method .\n  }\n}\nORDER BY ?resolution""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX PDBo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\n\nSELECT ?pdbid ?resolution \nWHERE {\n  ?datablock a PDBo:datablock ;\n             PDBo:datablockName ?pdbid .\n  \n  FILTER (?pdbid IN (\""2PCX\"", \""2XWR\"", \""2OCJ\"", \""1UOL\""))\n  \n  ?datablock PDBo:has_refineCategory ?refine_cat .\n  ?refine_cat PDBo:has_refine ?refine .\n  ?refine PDBo:refine.ls_d_res_high ?resolution .\n}\nORDER BY ?resolution""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX PDBo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\n\nSELECT DISTINCT ?property ?value\nWHERE {\n  <http://rdf.wwpdb.org/pdb/2PCX> ?property ?value .\n  FILTER(contains(str(?property), \""resolution\"") || contains(str(?property), \""Resolution\""))\n}\nLIMIT 50""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX PDBo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT ?pdbid ?res\nWHERE {\n  ?s PDBo:datablockName ?pdbid .\n  ?s PDBo:has_refine ?refine .\n  ?refine PDBo:refine.ls_d_res_high ?res .\n  FILTER(?pdbid = \""2PCX\"")\n}""}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""human p53 DNA-binding domain crystal structure highest resolution"", ""max_results"": 10}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""p53 core domain crystal structure"", ""max_results"": 10}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""34862374"", ""34224597"", ""29523774""]}}]",VALUABLE,High-resolution structures around 1.5-2.0 Å for p53 DNA-binding domain,"COMPLEX QUERY requiring cross-reference and numeric knowledge.

Databases/Resources: PDB

Knowledge Required:
- UniProt cross-reference for P04637 filtering
- xsd:decimal() conversion for resolution comparison
- ORDER BY with numeric conversion
- struct category for title/keyword filtering

Without proper knowledge: Cannot properly order by resolution.

Verified in pdb_exploration.md Patterns 1 and 2."
72,2026-02-01,Precision,What is the UniProt ID for the human insulin receptor?,True,True,True,0.5,"The UniProt ID for the human insulin receptor is **P06213**.

This entry corresponds to the INSR gene product, which is the insulin receptor protein in humans. The insulin receptor is a transmembrane receptor tyrosine kinase that plays a crucial role in glucose homeostasis and metabolic regulation.",,2.8744089603424072,50,69,True,True,0.5,"The UniProt ID for the human insulin receptor is **P06213**.

This entry corresponds to the Insulin receptor (IR), which is a tyrosine kinase receptor (EC 2.7.10.1) in humans (*Homo sapiens*). The protein is also known as CD220 and is cleaved into alpha and beta subunits.",,11.803425073623657,9,182,770,52261,mcp__togomcp__search_uniprot_entity,"[{""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""human insulin receptor"", ""limit"": 5}}]",VALUABLE,P06213 (INSR_HUMAN),"SIMPLE QUERY - Straightforward protein lookup.

Method: search_uniprot_entity('human insulin receptor')

Demonstrates when basic protein search tools suffice.

Verified in uniprot_exploration.md simple queries section."
